Filing Flows › TG Therapeutics (TGTX) › Capital expenditures
TG Therapeutics (TGTX) capital expenditures by quarter
TG Therapeutics' capital expenditures were $293K in Q2 2026 (second quarter 2026), +337% from Q4 2025. Over the last 3 quarters it ranged from $42K (Q2 2025) to $293K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $293K | +337% | +598% |
| Q4 2025 | $67K | +60% | — |
| Q2 2025 | $42K | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' capital expenditures?
TG Therapeutics' capital expenditures were $293K in Q2 2026 (second quarter 2026), +337% from Q4 2025.
How has TG Therapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $42K (Q2 2025) to $293K (Q2 2026).